| Document |
Document Title |
|
WO/2006/052886A1 |
The invention relates to metabolites of certain [1,4]diazepino[6,7,1-i~]quinoline derivatives and methods of preparation and use thereof. Specifically, the invention relates to compounds of formula I wherein the various substituents are ...
|
|
WO/2006/052930A1 |
The present invention is directed to analogs of paromomycin having a variety of chemical functional groups attached at the 2”-O-positions as well as their preparation and use as prophylactic or therapeutics against microbial infection.
|
|
WO/2006/048165A1 |
The invention relates to preparations containing (a) alkyl- and/or alkenyl oligoglycosides of formula (I), R1O-[G]p, in which R1 represents a linear or branched alkyl- and/or alkenyl group comprising between 4 and 22 carbon atoms, G repr...
|
|
WO/2006/046674A1 |
A medicinal composition for preventing or treating hepatitis C virus infection which contains an extract of a plant belonging to the genus Polygala as the active ingredient. It is preferable that this medicinal composition contains an ex...
|
|
WO/2006/043705A1 |
A cubic liquid crystal composition, characterized by containing at least one amphiphilic compound which is represented by the general formula (1) and has an IV/OV value of 0.65 to 0.95 and water or an aqueous solvent: (1) wherein R is a ...
|
|
WO/2006/038221A1 |
A process for the production of steviosides from Stevia rebaudiana Bertoni includes extraction of comminuted plant material by directly injecting steam into the extractor followed by filtration to get aqueous extract and alkali treatment...
|
|
WO/2006/038440A1 |
A novel process for producing a phenylglycoside derivative which comprises using an unprotected sugar as a starting material and causing a compound having a phenolic hydroxy group to act on the sugar. The phenylglycoside derivative is at...
|
|
WO/2006/037185A1 |
A compound of the general formula (I): wherein R1, R2, X1, X1', X2, X2', X3, X3', X4, X4' and X5 define various substituents and p is 0, 1 or 2. The invention also relates to use of the compounds as anti-microbial agents.
|
|
WO/2006/037159A1 |
A method of identifying biologically active compounds with defined selectivity profile comprises: (c) designing a library of compounds of formula (1) to scan molecular diversity; and (d) assaying the library of compounds in at least two ...
|
|
WO/2006/034489A2 |
A compound of the formula (I) A method is also provided for treating diabetes and related diseases employing the above compound alone or in combination with another therapeutic agent.
|
|
WO/2006/029837A1 |
The invention relates to a method for directly reacting an amino alcohol, which has at least one hydroxyl function and at least one amino function, with an organic compound as a substrate, which comprises at least one acidic, functional ...
|
|
WO/2006/027987A1 |
A compound usable as a preventive or therapeutic agent for urination disorders. It is a compound represented by the following general formula (1), a pharmacologically acceptable salt of the compound, or a hydrate or solvate of either. Al...
|
|
WO/2006/027784A2 |
A novel group of aminoglycosides which share some structural features of currently available aminoglycosides, while also having significant structural differences, is disclosed. The similarity enables these aminoglycosides to be highly p...
|
|
WO/2006/028229A1 |
A dicarboxylic acid compound obtained by oxidative decomposition of the second sugar residue of the sugar chain of a pradimicin group antibiotic, namely, an antibiotic composed of a benzonaphthacenequinone skeleton, D-amino acid side cha...
|
|
WO/2006/029065A1 |
Disclosed are prodrugs of inactivators of 06-alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the (3-glucuronidase enzyme, which is either administered to the patient or produced by necrotic tumor cells. The prodrug...
|
|
WO/2006/024926A1 |
The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and au...
|
|
WO/2006/026639A1 |
A process for the preparation of an alkoxylated sucrose ester including the steps of: forming an initial reaction mixture of a sucrose ester and from about 0.01% to about 5% of a catalyst; and forming an initial reaction product by react...
|
|
WO/2006/026638A1 |
Purified alkoxylated sucrose esters of the formula (I): wherein R is independently selected from: COR'; (CH2CH2O)xH; and (CH2CH2O)x COR'; wherein R' is a fatty acid compound having from about 2 to about 28 carbon atoms; and wherein x is ...
|
|
WO/2006/022325A1 |
It is intended to provide a novel and useful galactose derivative constituting a drug carrier by which a drug can be efficiently transported into the liver, a drug carrier containing this derivative and a medicinal composition containing...
|
|
WO/2006/017726A2 |
The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provid...
|
|
WO/2006/016997A2 |
Compounds that are adjuvants and immunoeffectors are described and claimed. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for us...
|
|
WO/2006/008141A1 |
The invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates or pharmaceutically acceptable formulations thereof. These compounds can be used for inhibiting factor Xa and for preventing and/o...
|
|
WO/2006/007794A1 |
Cis-l,2-substituted stilbene derivates or pharmaceutically acceptable salts, glycosides, solvates thereof, pharmaceutical compositions comprising said compounds, the use of said compounds for manufacturing medicaments for treating and/or...
|
|
WO/2006/005142A2 |
This invention provides novel biologically active monocyclic and polycyclic compounds, in particular bicyclic compounds, having some degree of structural similarity with the simmondsin scaffold, as well as monocyclic intermediates for ma...
|
|
WO/2006/006496A1 |
A process for producing azulene derivatives useful as Na+-glucose cotransporter inhibitor easily and simply in high yield at a low cost which is industrially advantageous and excellent in environmental protection, characterized by subjec...
|
|
WO/2006/005681A1 |
A process for preparing a pulverulent alditol acetal composition, which comprises a) mixing, in the presence or absence of other constituents, an aqueous alditol acetal composition having a solids content (SC) of between 40 and 75%, rela...
|
|
WO/2006/003107A1 |
The invention relates to the use of a malic acid glucoside [2-(glucosyl)-butane-1,4-diacid] or of a physiologically acceptable salt of a malic acid glucoside as flavouring substance, in particular as umami flavouring substance and taste ...
|
|
WO/2006/003518A2 |
The present invention relates to carbohydrate-phosphorylcholine conjugate molecule, and more particularly to phosphorylcholine-N-acetyl-D-galactosamine molecules and their use for treating and/or preventing a bacterial infection of the r...
|
|
WO/2006/001374A1 |
Disclosed is a radiosensitizer containing, as an active constituent, at least one compound selected from the group consisting of compounds represented by the general formula (1) below and pharmacologically acceptable salts thereof. (1) (...
|
|
WO/2005/123711A1 |
The present invention relates to pharmaceutics and organic chemistry. The invention discloses a new kind of bicyclol glycosides and the preparation method thereof. The method comprises bicyclol being reacted with trichloroimide ester of ...
|
|
WO/2005/118777A2 |
The invention relates to a novel strain Saccharothrix actinomycete SA 103 deposited at CNCM on 16th February 2004, number I-3160 or a mutant strain thereof; a method and a medium for selection of said strain; and a method for the product...
|
|
WO/2005/116041A2 |
New amino glycoside compounds or derivatives thereof having at least one sugar moiety and which comprise two or more cyclic structures capable of forming “charmed” structural features at physiological pH, and which have binding affin...
|
|
WO/2005/116042A1 |
The present invention relates to ginsenoside derivatives effective in prevention and treatment of cancer. More specifically, the present invention relates to ginsenoside derivatives with novel structures effective in prevention and treat...
|
|
WO/2005/113011A2 |
In one aspect, this invention is directed to prodrugs of ion channel modulating compounds, wherein the prodrug comprises an ion channel modulating compound attached to one or more prodrug moieties. In another aspect, this invention is di...
|
|
WO/2005/113568A1 |
The present invention relates to novel galactosides and the use of the galactosides as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galactin to receptors in a mammal. ...
|
|
WO2004058789A9 |
Sugar-chain asparagine derivatives having undeca- to tri-saccharides as represented by the general formula (1): (1) [wherein R<1> and R<2> are each independently hydrogen or a group represented by one of the general formulae (2) to (6) s...
|
|
WO/2005/107769A1 |
It is intended to provide an oral flora-improving agent capable of forming a favorable flora in the oral cavity and a food or a drink for improving the oral flora. An oral flora-improving agent comprising a ganglioside as the active ingr...
|
|
WO/2005/103064A1 |
A sugar chain-supported carbosilane dendrimer represented by the following general formula (1): (R1)mSi&lcub -R2-Si(R6)l[R3-Si(R7)k(R4-S-R5-A)3-k]3-l&rcub n, the following general formula (2): (R1)mSi[-R2-Si(R6)l(R4-S-R5-A)3-l], or the f...
|
|
WO/2005/103065A1 |
The present invention relates to new anthracycline derivatives and their use in cancer therapy and diagnosis. These anthracycline derivatives can be radiolabelled and used as an imaging agent in cancer diagnosis. The radiolabelled anthra...
|
|
WO/2005/100374A1 |
The present invention relates generally to chemical agents useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory including allergic diseases, metastatic cancers...
|
|
WO/2005/100373A2 |
The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and au...
|
|
WO/2005/099338A2 |
[PROBLEMS] To provide a sugar-chain primer for making a cell to synthesize O-glycan from among glycoprotein type sugar chains. [MEANS FOR SOLVING PROBLEMS] A sugar-chain primer for the synthesis of an O-glycan type sugar chain in a cultu...
|
|
WO/2005/097815A1 |
A process for mass producing soyasaponin B being a raw material for therapeutic agent for hepatitis ME3738 (methyl derivative of soyasapogenol B) at low cost. There is provided a process for producing group B saponin, characterized by in...
|
|
WO/2005/094897A2 |
This invention is directed to PEGlyated derivatives, drug conjugates and isotopic derivatives of certain ion channel modulating compounds. Pharmaceutical compositions and methods of use of also disclosed
|
|
WO/2005/094858A1 |
It is intended to provide an antidiabetic composition containing an active ingredient originating in a natural plant which can be obtained and taken in daily diet, inhibits hyperglycemia after eating to thereby efficaciously relieve the ...
|
|
WO/2005/095429A1 |
A phenol derivative represented by the following general formula (I), a pharmacologically acceptable salt of the derivative, or a prodrug of either. They have human SGLT inhibitory activity and are useful as a preventive or therapeutic a...
|
|
WO/2005/095410A1 |
The present invention relates to methods for the preparation of diastereomerically pure (3R,3aS,6aR) hexahydro-furo[2,3-b]furan-3-ol (6) as well as a novel intermediate, (3aR,4S,6aS) 4-methoxy-tetrahydro-furo[3,4-b]furan-2-one (4) for us...
|
|
WO/2005/095941A1 |
A mass analysis method for a derivative of an organic residue containing a sulfur atom, characterized in that it comprises ionizing a derivative of an organic residue containing said sulfur atom from a metal-organic residue composite whe...
|
|
WO/2005/094878A1 |
It is intended to provide a medicinal composition for transferring a chemotherapeutic agent (preferably an anticancer agent) into a cell or a living body by using a virus envelope vector. For achieving this purpose, a medicinal compositi...
|
|
WO/2005/091754A2 |
Novel compounds and methods useful in the control, treatment, and prevention of fungal activity.
|
